S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Banking Nightmare (Ad)
Adele extends Las Vegas residency, plans concert film
Union Pacific 2nd railroad to drop push for one-person crews
Modern Day Options Trading For Beginners! (Ad)pixel
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
These Indicators Are Pointing To a Rally In Bank Of America, Soon
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Banking Nightmare (Ad)
Adele extends Las Vegas residency, plans concert film
Union Pacific 2nd railroad to drop push for one-person crews
Modern Day Options Trading For Beginners! (Ad)pixel
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
These Indicators Are Pointing To a Rally In Bank Of America, Soon
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Banking Nightmare (Ad)
Adele extends Las Vegas residency, plans concert film
Union Pacific 2nd railroad to drop push for one-person crews
Modern Day Options Trading For Beginners! (Ad)pixel
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
These Indicators Are Pointing To a Rally In Bank Of America, Soon
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Banking Nightmare (Ad)
Adele extends Las Vegas residency, plans concert film
Union Pacific 2nd railroad to drop push for one-person crews
Modern Day Options Trading For Beginners! (Ad)pixel
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
These Indicators Are Pointing To a Rally In Bank Of America, Soon
NASDAQ:SELB

Selecta Biosciences - SELB Stock Forecast, Price & News

$1.41
-0.04 (-2.76%)
(As of 03/24/2023 08:51 PM ET)
Add
Compare
Today's Range
$1.38
$1.46
50-Day Range
$1.26
$1.89
52-Week Range
$0.65
$2.73
Volume
836,000 shs
Average Volume
1.29 million shs
Market Capitalization
$216.18 million
P/E Ratio
10.85
Dividend Yield
N/A
Price Target
$6.00

Selecta Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
325.5% Upside
$6.00 Price Target
Short Interest
Bearish
5.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.46mentions of Selecta Biosciences in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$38,408 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

118th out of 995 stocks

Pharmaceutical Preparations Industry

45th out of 482 stocks


SELB stock logo

About Selecta Biosciences (NASDAQ:SELB) Stock

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
The Latest Analyst Ratings for Selecta Biosciences
Selecta Biosciences (NASDAQ:SELB) Price Target Cut to $4.00
BTIG Sticks to Their Buy Rating for Selecta Biosciences (SELB)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
SVB Securities Keeps Their Buy Rating on Selecta Biosciences (SELB)
See More Headlines
Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Company Calendar

Last Earnings
3/02/2023
Today
3/27/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SELB
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+325.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$35.38 million
Pretax Margin
31.39%

Debt

Sales & Book Value

Annual Sales
$110.78 million
Cash Flow
$0.09 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
106,557,000
Market Cap
$216.18 million
Optionable
Optionable
Beta
1.17

Key Executives

  • Carsten BrunnCarsten Brunn
    President, Chief Executive Officer & Director
  • Lloyd Johnston
    COO, Senior Vice President-Research & Development
  • Blaine T. Davis
    Chief Financial Officer
  • Takashi Kei Kishimoto
    Chief Scientific Officer
  • Peter G. TraberPeter G. Traber
    Chief Medical Officer













SELB Stock - Frequently Asked Questions

Should I buy or sell Selecta Biosciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SELB shares.
View SELB analyst ratings
or view top-rated stocks.

What is Selecta Biosciences' stock price forecast for 2023?

5 brokers have issued twelve-month target prices for Selecta Biosciences' stock. Their SELB share price forecasts range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 325.5% from the stock's current price.
View analysts price targets for SELB
or view top-rated stocks among Wall Street analysts.

How have SELB shares performed in 2023?

Selecta Biosciences' stock was trading at $1.13 at the beginning of the year. Since then, SELB shares have increased by 24.8% and is now trading at $1.41.
View the best growth stocks for 2023 here
.

When is Selecta Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SELB earnings forecast
.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its earnings results on Thursday, March, 2nd. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The business had revenue of $16.80 million for the quarter, compared to the consensus estimate of $12.72 million. Selecta Biosciences had a trailing twelve-month return on equity of 15.67% and a net margin of 31.94%.

What ETFs hold Selecta Biosciences' stock?

ETFs with the largest weight of Selecta Biosciences (NASDAQ:SELB) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).First Trust Dow Jones Select Microcap Index Fund (FDM).

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Endurant Capital Management LP (2.47%), JPMorgan Chase & Co. (1.32%), Millennium Management LLC (1.08%), Marshall Wace LLP (0.86%), Renaissance Technologies LLC (0.80%) and Geode Capital Management LLC (0.77%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends
.

How do I buy shares of Selecta Biosciences?

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $1.41.

How much money does Selecta Biosciences make?

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $216.18 million and generates $110.78 million in revenue each year. The company earns $35.38 million in net income (profit) each year or $0.13 on an earnings per share basis.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.

This page (NASDAQ:SELB) was last updated on 3/27/2023 by MarketBeat.com Staff